2024
Impact of Atopic Dermatitis (Eczema) and Its Treatment on the Risk of Adverse Events Following Total Knee Arthroplasty
Smith-Voudouris J, Dhodapkar M, Halperin S, Cohen J, Grauer J. Impact of Atopic Dermatitis (Eczema) and Its Treatment on the Risk of Adverse Events Following Total Knee Arthroplasty. JAAOS Global Research And Reviews 2024, 8: e23.00267. PMID: 39436712, PMCID: PMC11498930, DOI: 10.5435/jaaosglobal-d-23-00267.Peer-Reviewed Original ResearchConceptsAtopic dermatitisAdverse eventsOdds of pneumoniaTotal knee arthroplastyPerioperative outcomes of patientsModerate-to-severe diseaseIncreased oddsEmergency departmentUrinary tract infectionChronic inflammatory skin conditionOutcomes of patientsLog-rank testRisk of adverse eventsInflammatory skin conditionIncreased odds of pneumoniaKnee arthroplastyTotal knee arthroplasty patientsPerioperative outcomesImmunosuppressive medicationsTract infectionsAggregate adverse eventsAdult patientsImpact of atopic dermatitisPatient characteristicsMultivariate analysisBiologics for Psoriasis
Wride A, Chen G, Spaulding S, Tkachenko E, Cohen J. Biologics for Psoriasis. Dermatologic Clinics 2024, 42: 339-355. PMID: 38796266, DOI: 10.1016/j.det.2024.02.001.Peer-Reviewed Original ResearchConceptsIL-23IL-17ALong-term risk-benefit profileTNF-aLong-term adverse eventsIL-23 inhibitorsTumor necrosis factor-alphaP19 subunit of IL-23Risk-benefit profileSubunit of IL-23TNF-a inhibitorsTreatment of psoriasisNecrosis factor-alphaHigher Psoriasis AreaRates of short-termIL-12/23Psoriasis AreaIL-17FAdverse eventsIL-12IL-17Factor-alphaP19 subunitInjectable biologicsP40 subunit
2023
Immune checkpoint inhibitor-induced bullous pemphigoid is characterized by interleukin (IL)-4 and IL-13 expression and responds to dupilumab treatment
Shipman W, Singh K, Cohen J, Leventhal J, Damsky W, Tomayko M. Immune checkpoint inhibitor-induced bullous pemphigoid is characterized by interleukin (IL)-4 and IL-13 expression and responds to dupilumab treatment. British Journal Of Dermatology 2023, 189: 339-341. PMID: 37140007, PMCID: PMC10947518, DOI: 10.1093/bjd/ljad149.Peer-Reviewed Original ResearchConceptsIL-13 expressionBullous pemphigoidImmune-related adverse eventsComplete disease clearancePromising new therapyNovel therapeutic approachesDisease clearanceAdverse eventsTumor immunityTherapeutic approachesNew therapiesConventional treatmentPemphigoidInterleukinTreatmentPatientsExpressionTherapyImmunityClearanceThe effect of baseline eczema or psoriasis on the morphology of cutaneous immune-related adverse events due to immune checkpoint inhibitor therapy
Belzer A, Mortlock R, Pach J, Cohen J, Leventhal J. The effect of baseline eczema or psoriasis on the morphology of cutaneous immune-related adverse events due to immune checkpoint inhibitor therapy. Journal Of The American Academy Of Dermatology 2023, 88: 1198-1200. PMID: 36634749, PMCID: PMC10121758, DOI: 10.1016/j.jaad.2023.01.002.Peer-Reviewed Original Research